Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E van Rijswijk

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The Netherlands Journal of Medicine|January 1, 1986
New prospects for immune status assessment in Hodgkin's diseaseR E Van Rijswijk
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1992
Suramin awakes?H M Pinedo, R E van Rijswijk
Drugs & Aging|August 10, 2000
Drug therapy for gynaecological cancer in older womenR E van Rijswijk, J B Vermorken
Cancer|January 1, 1984
A prospective study of the changes in immune status following radiotherapy for Hodgkin's diseaseR E van Rijswijk, J P Sybesma, L Kater
Cancer|February 15, 1983
A prospective study of the changes in the immune status before, during, and after multiple-agent chemotherapy for Hodgkin's diseaseR E Van Rijswijk, J P Sybesma, L Kater
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
A case of brain metastases from male breast cancer responding to tamoxifenR E van Rijswijk, R J van Oostenbrugge, A Twijnstra
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 1, 1996
A clarithromycin-induced myasthenic syndromeE Pijpers, R E van Rijswijk, B Takx-Köhlen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteriaR E van Rijswijk, E Cvitkovic, J Wagstaff, et al.
Cancer|April 15, 1986
Five-year survival in Hodgkin's disease. The prospective value of immune status at diagnosisR E van Rijswijk, A de Meijer, J P Sybesma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998
Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual diseaseR E van Rijswijk, K Hoekman, C W Burger, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The Netherlands Journal of Medicine|January 1, 1986
New prospects for immune status assessment in Hodgkin's diseaseR E Van Rijswijk
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1992
Suramin awakes?H M Pinedo, R E van Rijswijk
Drugs & Aging|August 10, 2000
Drug therapy for gynaecological cancer in older womenR E van Rijswijk, J B Vermorken
Cancer|January 1, 1984
A prospective study of the changes in immune status following radiotherapy for Hodgkin's diseaseR E van Rijswijk, J P Sybesma, L Kater
Cancer|February 15, 1983
A prospective study of the changes in the immune status before, during, and after multiple-agent chemotherapy for Hodgkin's diseaseR E Van Rijswijk, J P Sybesma, L Kater
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
A case of brain metastases from male breast cancer responding to tamoxifenR E van Rijswijk, R J van Oostenbrugge, A Twijnstra
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 1, 1996
A clarithromycin-induced myasthenic syndromeE Pijpers, R E van Rijswijk, B Takx-Köhlen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteriaR E van Rijswijk, E Cvitkovic, J Wagstaff, et al.
Cancer|April 15, 1986
Five-year survival in Hodgkin's disease. The prospective value of immune status at diagnosisR E van Rijswijk, A de Meijer, J P Sybesma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998
Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual diseaseR E van Rijswijk, K Hoekman, C W Burger, et al.
Pageof 3